Rodman & Renshaw maintained its NuVasive NUVA Market Perform rating in a research report published today.
In the report, Rodman & Renshaw states, "Street estimates for NuVasive, in our opinion, still remain aggressive and account for substantial operating synergies. NuVasive's business model is highly sensitive to SG&A levels and inherently has a high cost of producing revenues."
Shares of NuVasive were trading at $30.38 at the time of posting, down 6.13% from Monday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in